EXCLUSIVE: Alcohol Disorder Focused Adial Pharmaceuticals Secures US Patent
EXCLUSIVE: Alcohol Disorder Focused Adial Pharmaceuticals Secures US Patent
On April 16, 2024, the United States Patent and Trademark Office issued patent number 11957664 to Adial Pharmaceuticals Inc (NASDAQ:ADIL).
2024年4月16日，美國專利商標局向阿迪爾製藥公司（納斯達克股票代碼：ADIL）頒發了專利號爲11957664的專利。
This patent expands Adial's intellectual property protection and covers the combination of the company's proprietary genetic diagnostic to identify patients with specific genotypes for genetically targeted treatment of alcohol use disorder (AUD) and other drug dependencies, such as opioid use disorder (OUD), with the company's lead investigational new drug product AD04.
該專利擴大了Adial的知識產權保護，涵蓋了該公司專有的基因診斷與該公司主要研究新藥產品AD04相結合，該診斷旨在識別具有特定基因型的患者，用於酒精使用障礙（AUD）和其他藥物依賴的基因靶向治療，例如阿片類藥物使用障礙（OUD）。
Related: EXCLUSIVE: Adial Pharmaceuticals Announces New US Patent Covering Its Molecular Genetic Diagnosing For Alcohol, Drug Dependence.
相關： 獨家：Adial Pharmicals宣佈新的美國專利，涵蓋其酒精和藥物依賴的分子遺傳學診斷。
Cary Claiborne, CEO of Adial, commented, "We are proud to have secured this new patent, which covers important aspects of the combination of our proprietary genetic diagnostic and AD04 to treat AUD, OUD, and other drug dependencies."
Adial首席執行官Cary Claiborne評論說：“我們很自豪能夠獲得這項新專利，該專利涵蓋了我們專有的基因診斷與AD04相結合以治療AUD、OUD和其他藥物依賴的重要方面。”
"Importantly, we have identified specific genotypes that responded with clinically meaningful changes in drinking behavior compared to placebo in the AD04 post hoc analysis, representing an addressable market of approximately $40 billion in the U.S. alone," Claiborne added.
克萊伯恩補充說：“重要的是，在AD04事後分析中，與安慰劑相比，我們已經確定了特定的基因型，這些基因型的飲酒行爲會發生具有臨床意義的變化，僅在美國就有約400億美元的潛在市場。”
In February, Adial Pharmaceuticals received a U.S. patent allowance covering AD04 and its ability to target the serotonin transporter gene for the potential treatment of opioid use disorder.
2月，Adial Pharmicals獲得了一項美國專利許可，涵蓋AD04及其靶向血清素轉運體基因以潛在治療阿片類藥物使用障礙的能力。
Earlier this month, Adial Pharmaceuticals exclusively told Benzinga regarding the publication of a peer-reviewed article highlighting the clinical results, strong safety profile, and high compliance among patients administered AD04 (low-dose ondansetron).
本月早些時候，Adial Pharmicals獨家表示 本辛加 關於發表一篇經過同行評審的文章，該文章重點介紹了服用AD04（低劑量恩丹西酮）的患者的臨床結果、良好的安全性和高依從性。
The publication also reported the results of a new study analyzing the liver safety profile of AD04 compared with placebo in subjects with AUD in the company's prior Phase 3 trial.
該出版物還報告了一項新研究的結果，該研究分析了該公司先前的3期試驗中AD04與安慰劑對比的AUD受試者的肝臟安全性。
Price Action: ADIL shares closed at $1.93 on Friday.
價格走勢：週五，ADIL股價收於1.93美元。